MEVAC for Vaccines

What MEVAC for Vaccines does

MEVAC for Vaccines (Middle East for Vaccines) is a privately held Egyptian-American veterinary vaccine manufacturer founded in 2011 and headquartered in Cairo. The company develops, manufactures, and distributes live attenuated, inactivated, water-in-oil emulsion, recombinant, and vector vaccines for poultry, ruminants, aquaculture, equine, and rabbit species, with a portfolio of more than 74 vaccines covering 14 disease indices. Its flagship MEFLUVAC H5 range addresses Avian Influenza subtypes H5N1 and H5N8 and is positioned as market-leading in the Middle East and Africa. Operations span four manufacturing sites with four production lines, including BSL2 and BSL3 equipped laboratories, and a third factory in El Salheia El Gedida dedicated to recombinant and genetically engineered vaccines under construction since 2020. The company operates through an enterprise B2B distribution model with regional headquarters in Egypt, UAE, and Saudi Arabia, exporting to over 30 countries as of 2023 with a stated plan to reach 90 countries by 2027.

The customer base is concentrated in commercial poultry and livestock operations across the Middle East, Africa, and parts of Asia, with secondary exposure to fish farms and equine industry buyers. Pricing is quote-based B2B with no public disclosure, consistent with the enterprise sales motion. The company employs 450 professionals across seven nationalities, including 30 PhD holders, 35 MVSc holders, and 75 bachelor-level staff, plus 42 R&D scientists, veterinarians, and biotechnologists. Facilities hold GMP accreditation with EU-GMP and PIC/S GMP certifications recognized in 7+ countries, alongside ISO 9001, 14001, 45001, 50001, and 17025 and OIE compliance, establishing the regulatory credentials needed to compete in regulated veterinary markets. Strategic American partnership with Kemin Industries supports international distribution of vaccines made in Egypt.

Revenue is not publicly disclosed, but the combination of 450 staff, four production lines, a 30+ country export footprint, and ongoing capacity expansion supports a mid-sized emerging-market veterinary manufacturer profile. Growth is driven by geographic expansion, the MEVAC III BSL3 vector/recombinant capacity buildout, and the Kemin-led international channel buildout. No AI/ML capabilities are evidenced in the source data, consistent with a traditional biomanufacturing model rather than a digitally native business.

Name

MEVAC for Vaccines

Legal name

Middle East for Vaccines (MEVAC)

Website

https://me-vac.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

251–500 employees

Short description

MEVAC for Vaccines is an Egyptian-American veterinary vaccine manufacturer founded in 2011, producing 74+ vaccines for poultry, ruminants, aquaculture, equine, and rabbits across 14 disease indices. It is the market leader in Avian Influenza H5N1/H5N8 vaccines in the Middle East and Africa, exporting to 30+ countries.

Ownership category

akta.pro rank

Product category

Veterinary Vaccines

NAICS

Pharmaceutical Preparation Manufacturing (325412)

akta.pro primary industry

Veterinary Vaccines (HLAIAEAH)

akta.pro secondary industries

Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA) (HLAMAKAH), Poultry Vaccines (HLAMAKAC), Livestock Vaccines (Cattle, Swine, Sheep & Goats) (HLAMAKAB), Vaccine R&D, Clinical/Field Trials & Regulatory Affairs (HLAMAKAM), Veterinary Vaccines (Biologics) (HLAMAEAL)

Keywords

• Veterinary vaccines
• Animal health products
• Poultry vaccines
• Avian influenza vaccines
• Livestock biologics

Headquarters

HQ city

Cairo

HQ country

Egypt

HQ region

Africa

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Veterinary Vaccine Manufacturing & Distribution: MEVAC generates revenue through manufacturing and distributing high-quality vaccines for poultry, ruminants, aquaculture, and equine species. The company operates four production lines across four manufacturing sites, serving both domestic Egyptian market and exporting to international markets through an extensive distribution network.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

MEVAC for Vaccines (Middle East for Vaccines) is an Egyptian-based veterinary biopharmaceutical manufacturer that develops, produces, and distributes a portfolio of more than 74 vaccines for poultry, ruminants, aquaculture, equine, and rabbits. The company operates four GMP-certified manufacturing sites producing live attenuated, inactivated, water-in-oil emulsion, and recombinant vaccines, with particular strength in Avian Influenza (H5N1 and H5N8) vaccines under its MEFLUVAC H5 brand.

Product overview

MEVAC for Vaccines is a comprehensive veterinary vaccine manufacturer offering more than 74 vaccines covering Poultry, Ruminants, Equine, Rabbits, and Aquaculture species across 14 disease categories. The portfolio includes both live attenuated and inactivated vaccines, with the MEFLUVAC H5 product line being the company's market-leading Avian Influenza vaccine brand (H5N1 and H5N8). Products span across five main categories: Poultry Vaccines (including MEFLUVAC, MEVAC ND, MEVAC IB, RINNOVAC, Coryvac lines), Ruminants Vaccines (including Aphthovac multivalent FMD vaccines, MEVAC LSD, MEVac HS), Equine Vaccines, Rabbits Vaccines (including MYXO VAC, ME Vac HS), and Aqua Vaccines (Mevac Aquastrept). The company operates four production lines across four manufacturing sites with GMP accreditation.

Differentiator

Problem solved

Functional benefit

Products and services

• MEFLUVAC H5 Range
• MEVAC ND Range
• MEVAC IB Range
• RINNOVAC
• Coryvac
• MEVAC IBD 818
• Aphthovac Range
• MEVAC LSD / Lumpy Vac Lumpy Skin Disease vaccines for cattle, addressing a major transboundary ruminant disease.
• MEVac HS
• ME Vac RHD
• ME Bunny Vac
• MYXO VAC
• Mevac Aquastrept
• Vaccination Services

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered flagship and core.

• Kemin IndustriesflagshipStrategic or Co-development Partner · 1 January 2021Strategic American partnership for global distribution of MEVAC's Made in Egypt vaccines. Kemin serves as the international strategic partner facilitating worldwide distribution of MEVAC products. Collaboration includes joint training programs and continuous development initiatives for MEVAC's global team.
• United BioMed (UBM)coreStrategic or Co-development Partner · 1 January 2020Cooperation partnership for supporting livestock, poultry and fish health in Egypt and worldwide through joint scientific conferences and innovative solutions development.
• Egyptian-American International PartnershipflagshipStrategic or Co-development PartnerFounding partnership structure combining Egyptian and American expertise in veterinary vaccine development, manufacturing, and global distribution.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Peers

• Indian Immunologicals:

Direct peers

• Ceva Santé Animale: French animal health company with one of the strongest global poultry vaccine portfolios, including avian influenza vaccines. Highly comparable as a focused animal vaccine manufacturer competing head-to-head with MEVAC's MEFLUVAC line in MEA and emerging markets.
• Hester Biosciences: Indian veterinary vaccine manufacturer focused on poultry and livestock vaccines, exporting to emerging markets. Comparable as a regionally focused animal vaccine producer targeting similar disease indices (Newcastle, IB, FMD) and similar customer segments.
• Vaxxinova: Netherlands-based animal health company specialized in poultry and livestock vaccines and diagnostics. Comparable as a focused animal vaccine manufacturer with strong MEA and emerging market presence, competing in similar poultry and livestock disease categories as MEVAC.

Broad incumbents

• Elanco Animal Health: US-listed animal health major with a poultry and livestock vaccine and therapeutics portfolio following its Bayer Animal Health acquisition. Comparable as a multinational competitor in the same animal vaccine markets as MEVAC.
• Merck Animal Health: Major animal health division of MSD with a large veterinary biologics portfolio including poultry and livestock vaccines. Comparable because it competes in the same government and integrator tenders that MEVAC targets across its 30+ export countries.
• Zoetis: Global #1 animal health company offering poultry, livestock, and aquaculture vaccines. Comparable because it sells into the same customer segments (poultry integrators, livestock farms) that MEVAC targets, though it competes across a much broader portfolio and geographies.
• Phibro Animal Health: US animal health company with a meaningful poultry vaccine and nutritional specialty products business serving emerging markets. Comparable because it serves the same poultry integrator customers and competes in similar MEA and Asian markets as MEVAC.
• Boehringer Ingelheim Animal Health: Top-3 global animal health player with a strong poultry and livestock vaccine franchise (e.g., VAXXINOVA, avian influenza portfolio). Comparable as a direct competitor in poultry vaccine tenders in MEA and other emerging markets where MEVAC exports.

Regional players

• JOVAC (Jordan Bio-Industries Center): Jordanian veterinary vaccine manufacturer producing poultry, livestock, and equine vaccines for the MEA region. Comparable as a regionally focused animal vaccine producer with similar disease and species coverage to MEVAC, serving overlapping MEA customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/mevac1
• Xx.com/MEVAC_eg

Compliance11 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MEVAC for Vaccines